Trends in contraceptive use among women with human immunodeficiency virus

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 783-790

  Sun, Mengyang ^b   Peipert, Jeffrey F ^b   Zhao, Qiuhong ^b   Wilson, Tracey E ^b   Weber, Kathleen M ^b   Sanchez Keeland, Lorraine ^b   D'Souza, Gypsyamber ^b   Young, Mary ^b   Watts, D Heather ^b   Keller, Marla J ^b   Cohan, Deborah ^b   Massad, L Stewart ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; LONG ACTING REVERSIBLE CONTRACEPTIVE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONDOM; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PILL; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEMI STRUCTURED INTERVIEW; SEROLOGY; SEXUAL BEHAVIOR; TREND STUDY; UNPLANNED PREGNANCY; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CONDOMS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MODELS, STATISTICAL; SELF REPORT; UNITED STATES; YOUNG ADULT;

EID: 84866907574     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318269c8bb     Document Type: Article

References (31)

1. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: Increasing use of long-acting reversible contraception. Hum Reprod Update 2011;17: 121-37.
2. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105-13.
3. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010;29:1-44.
4. Kavanaugh ML, Jerman J, Hubacher D, Kost K, Finer LB. Characteristics of women in the United States who use longacting reversible contraceptive methods. Obstet Gynecol 2011; 117:1349-57.
5. Dehlendorf C, Foster DG, de Bocanegra HT, Brindis C, Bradsberry M, Darney P. Race, ethnicity and differences in contraception among low-income women: Methods received by Family PACT clients, California, 2001-2007. Perspect Sex Reprod Health 2011;43:181-7.
6. Lindsay MK, Grant J, Peterson HB, Willis S, Nelson P, Klein L. The impact of knowledge of human immunodeficiency virus serostatus on contraceptive choice and repeat pregnancy. Obstet Gynecol 1995;85:675-9.
7. Massad LS, Springer G, Jacobson L, Watts H, Anastos K, Korn A, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004;18: 281-6.
8. Wilson TE, Massad LS, Riester KA, Barkan S, Richardson J, Young M, et al. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: Results from the Women's Interagency HIV Study. AIDS 1999;13: 591-8.
9. Massad LS, Evans CT, Wilson TE, Golub ET, Sanchez-Keeland L, Minkoff H, et al. Contraceptive use among United States women with HIV. J Womens Health 2007;16: 657-66.
10. Kline A, Strickler J, Kempf J. Factors associated with pregnancy and pregnancy resolution in HIV seropositive women. Soc Sci Med 1995;40:1539-47.
11. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency Virus-1 infection. Endocr Rev 2010;31:79-97.
12. Centers for Disease Control and Prevention. The U. S. Medical Eligibility Criteria for Contraceptive Use, 2010.MMWRMorb Mortal Wkly Rep 2010;59:1-85.
13. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Kongitudinal study of men and women. Clin Infect Dis 2007;45:1377-85.
14. World Health Organization. Improving access to quality care in family planning: Medical eligibility criteria for initiating and continuing use of contraceptive methods. Geneva (Switzerland): World Health Organization; 1996.
15. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: A systematic review. AIDS 2009;23(Suppl 1):S55-67.
16. World Health Organization. Hormonal contraception and HIV: Technical statement. Available at: Http://www.who. int/reproductivehealth/topics/family- planning/Hormonal-contraception-and-HIV.pdf. Retrieved February 21, 2012.
17. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001;108: 784-90.
18. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1-8.
19. Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK, Overbaugh J, Panteleeff DD, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13: 2091-7.
20. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complication of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238-41.
21. Whiteman MK, Kissin DM, Samarina A, Curtis KM, Akatova N, Marchbanks PA, et al. Determinants of contraceptive choice among women with HIV. AIDS 2009;23(Suppl 1):S47-54.
22. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9: 117-25.
23. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005;12:1013-9.
24. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
25. Pruitt SL, von Sternberg K, Velasquez MM, Mullen PD. Condom use among sterilized and nonsterilized women in county jail and residential treatment centers. Womens Health Issues 2010;20:386-93.
26. Trussell J Contraceptive Efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, eds. Contraceptive Technology. 19th ed. New York (NY): Ardent Media; 2007:747-826.
27. Chu JH, Gange SJ, Anastos K, Minkoff H, Cejtin H, Bacon M, et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005;161:881-90.
28. Centers for Disease Control and Prevention. United States medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;18;59:1-86.
29. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
30. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA. Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 2012;119:762-71.
31. Madden T, Allsworth JE, Hladky KJ, Secura GM, Peipert JF. Intrauterine contraception in Saint Louis: A survey of obstetrician and gynecologists' knowledge and attitudes. Contraception 2010;81:112-6.